LIPELLA PHARMACEUTICALS INC. (LIPO)
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Lipella Pharmaceuticals Inc.
- 0.0%
- 1.2K
- 1.93
Float 4.40M · Signal8 dilution snapshot · Nov 14, 2025
The cost to borrow LIPO shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 98.9%
- 234
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 1.2K sh |
| Oct 15, 2026 | 1.2K sh |
| Sep 30, 2026 | 1.2K sh |
| Sep 15, 2026 | 1.2K sh |
| Aug 31, 2026 | 1.1K sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Sep 1, 2026 | 98.9% |
| Aug 11, 2026 | 100.0% |
| Aug 6, 2026 | 99.0% |
| Jul 17, 2026 | 13.0% |
130 calendar days requested; 4 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for LIPO: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 1,192 LIPO shares were sold short (0.03% of a 4.40M-share float, 1.93 days to cover).